Search Results

premium member , you can access over 500 minutes of exclusive, expert-led content from esteemed leaders, Drs

Here ’s what members get: Weekly deep dives from Dr.

Industry News Arcoscreen selected by START Lausanne to pitch at the START Global summit on the 23-24th Receptor 2 In Diabetic Retinopathy PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery Explore Dr

Watch Episode #177 Some scientific breakthroughs don’t start with a grant or a perfectly architected They start with a chance email, an unexpected visitor at the door, or the moment a team realizes the Their collaboration didn’t start as a big strategic play. It started with curiosity, openness, and the humility to admit that better answers required better tools this story resonates with your work or curiosity, go deeper. 🎧 Listen to the full conversation with Dr

postdoctoral training at Boston Children’s Hospital and Harvard Medical School, he joined the lab of Dr Starting Blue wasn’t glamorous.

At Dr. GPCR, we recognized this core problem.

Explore Dr. GPCR Ecosystem

It's starting to look a lot like Christmas at Dr. GPCR!

of Staff Postdoctoral Fellow, Biochemical And Cellular Pharmacology Project Leader, Biology Explore Dr

Receptor 2 In Diabetic Retinopathy PhD Opportunity - Novel P2y Receptor Ligands For Drug Discovery Explore Dr

Monthly AMAs  where you can challenge Dr. Kenakin with your own enzyme or GPCR interaction puzzles.

, you’re also unlocking over 500 minutes of exclusive, expert-led content from thought leaders like Drs

Developing Nations If you reside and work in a developing country, complete this form for free access to Dr

Thrilling beginning to Principles of Pharmacology I We are excited to announce the start of our Principles live and work  in a developing country, please complete this form to enjoy complimentary access to Dr

Explore Dr. GPCR Ecosystem

Developing Nations If you reside and work in a developing country, complete this form for free access to Dr

postdoctoral training, I joined one of the labs that participated in Latrophilins’ discovery, the lab of Dr Thomas Südhof, but did not start working on them right away.

Explore Dr. GPCR Ecosystem

Dr.

doesn’t immediately tell them who it’s for, why it matters, and what makes it different, then they start They have to guess why it matters, what the application is, and whether it fits. ✅ Start with relevance People start leaning in. You stop explaining. People start connecting the dots for you. 👉 This is what clarity creates. Start refining your message. Ready to Break Your Bottlenecks?

struggling to predict structures from scratch, Alessandro and others could now use AI-generated models as starting “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery

Where Biotech Misalignment Starts 👉 Most misalignment doesn’t start with conflict. It starts with silence. You assume your CSO knows where you’re headed. Your BD person starts framing it for a niche diagnostic use. The board expects an IND package. Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

Starting From Zero: Growing With a Mentor When Alessandro joined Prof. At the start it was difficult, because you see all these projects and you think, ah, I don’t know… but

. 👉 Start your journey with Terry’s foundational series Unlock "Unique Role of Pharmacology" now

If you're starting out in pharmacology, this lesson gives you the interpretive tools to ask smarter questions

“Companies started shutting down neuroscience and GPCR programs. But I stayed,” Sokhom said.

But Sokhom’s journey started differently.

the extracellular binding site of the GPCR, the protein changes into its active conformation , which starts to study therapeutic targets are fluorescent ligands , which are very useful in GPCR drug discovery, starting

schools and universities, research centers, governmental institutions, or private companies) Deadlines Start

study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start